![]() Putting a small volume around the ear reduces passive attenuation, which is part of the overall noise reduction, and a too-tight seal causes discomfort.īose has adopted a radical approach to the problem that includes holes in the earcup itself, which they call TriPort technology. For best ANR performance, the ideal is a small volume in front, on the ear side, with a large volume behind on the earcup side and a tight seal around the ear. Traditionally, ANR design is a compromise that must balance earcup volume, speaker size, clamping force and power requirements. At higher frequencies, the supposed improvement was less noticeable. The difference was most noticeable at the lower frequencies, where the Bose X virtually eliminated background rumble. Our volunteer testers unanimously agreed that the new Bose did a better job canceling noise than did the Series II we used for comparison. If the ergonomics work for you and you want the performance, its worth considering. For those upgrading from other headsets, even ANR models, the issue is clearer. At $995, the Aviation Headset X is no better a bargain than its predecessor, so unless youve got cash to burn, were not sure the Xs improved performance is worth upgrading from an older Series II. The bated-breath question of the day: Was the Bose worth the wait? It depends. Credit DRE and Peltor for delivering on their promises. In the end, Bose didnt start filling orders until December and as of this writing, LightSPEED wasnt expecting to do so until January, at the earliest. In whats fast becoming an annoying habit among avionics companies, both the Bose and LightSPEED proved to be further from production than claimed. And last, Peltor rolled out the Model 1750 Stratosphere, returning to the ANR market after a long absence. LightSPEED introduced its 25K, primarily a technological upgrade on the 20K, with expectations that it would equal Bose in performance.ĭRE Communications introduced the 6000enr, a conventional-looking David Clark-type design. The Bose Aviation Headset X created quite a stir, being a radical lightweight design purported to perform better than the market-leading Series II. ![]() It sold its 173,000-square-foot plant in Morris Plains, NJ, one of three, to Novartis in 2012 for $43 million to pick up some fast cash. Seattle-based Juno Therapeutics ($JUNO), which has Celgene ($CELG) as an investor, is leasing a plant in Bothell, WA, which will provide clinical supplies for now and commercial-scale production later.Last summers EAA AirVenture at Oshkosh saw the introduction of a number of advanced, third- and fourth-generation ANR headsets. In Novartis’ case, it acquired a specialized facility from the former Dendreon, which went bankrupt trying to establish its once-promising prostate cancer vaccine Provenge. Novartis ($NVS), which is leading in the field, has called its drug, which in early trials left 92% of patients cancer-free in a leukemia, "potentially curative." But because they are individualized, the manufacturing will cost much more than with other kinds of meds, which can rely on mass-production methods. Because they are expected to be one-time treatments, they are also anticipated to be expensive, running up to $450,000 if they are effective. Manufacturing is a key element of those working in the field. "Through our continuous efforts to optimize manufacturing, supply chain and quality control, our proprietary process now reduces the time from when a patient's materials are shipped to our facility to when the engineered T cells are returned to the patient to approximately 14 days, one of the fastest in the industry," Timothy Moore, Kite's executive VP of technical operations, said in a statement. Its location, next to the Los Angeles International Airport, was chosen, the company said in an announcement, to expedite receipt and shipment of engineered T cells from and to patients across the United States and Europe. Santa Monica, CA-based Kite said the plant is estimated to have the capacity to produce up to 5,000 patient therapies per year. The facility will initially produce product for clinical trials, but will be drafted into commercial production if Kite gets its lead candidate approved and launched next year as it hopes. ![]() That involves receiving from and then delivering individualized treated T cells to each patient. ![]() Kite Pharma ($KITE) opened its 43,500-square-foot plant in Los Angeles this week to produce chimeric antigen receptor (CAR) and T-cell receptor (TCR) product candidates. That is why Kite Pharma put its new plant next to an airport. The location of any pharma manufacturing plant is important-having it sited for optimal distribution-but it is essential with the new facilities being built to produce so-called CAR-T cell cancer treatments.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |